Study of AZD9829 in CD123+ Hematological Malignancies
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
56actual
Sites
22
Countries
Australia, China, Germany +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-31 | actual | When the study began enrolling |
| Primary completion | 2025-10-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-24 | actual | The whole study's end, after follow-up |
| First posted | 2023-12-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hematological Malignancies
Interventions
- Drug: AZD9829
- Drug: AZD9829
Primary outcomes
what the primary-completion date above is the date OFFrequency of dose limiting toxicities (DLTs).
measured Module 1 - 28 days.
Safety evaluation of AZD9829: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
measured Module 1 - From informed consent until 60 days after last dose of AZD9829.
Identify RP2D in R/R AML patients.
measured Moldule 1 -From informed consent until 60 days after last dose of AZD9829.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed